Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cholangiocarcinoma treatment with radiofrequency ablation or photodynamic therapy
2022-500107-50-00Phase 4Authorised
- Sponsor
- Leipzig University
- Start
- Aug 2022
- Modality
- Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of temoporfin and porfimer sodium in hilar cholangiocarcinoma (HC) (3 arms), sponsored by Leipzig University. Primary endpoint: Overall survival. Planned start Aug 2022; status: authorised.
02
Drugs
temoporfinporfimer sodium
03
Conditions
hilar cholangiocarcinoma (HC)
Beyond the preview
Go deeper on 2022-500107-50-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500107-50-00.